Arena Pharmaceuticals

(NASDAQ: ARNA)
Health Care  |  Biotechnology
80.35 0.86 1.08%
Stock Price | Feb. 26, 2021, 4 p.m.
0 Followers
Bid:
Ask:
Prev. Close: 79.49
52 Week Low: 32.95
52 Week High: 90.19
PE Ratio:
Dividend Yield: %

Company Summary

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Read more Read less

Recently Viewed Tickers

Premium An Urgent Market Update

66 Comments
3 months ago

Premium The Universe, week of March 23 2015

17 Comments
5 years ago

Premium The Universe, week of March 16 2015

42 Comments
5 years ago

Premium Livestox, January 21 2015

51 Comments
6 years ago

Premium The Universe, week of January 12 2015

9 Comments
6 years ago

Premium The Universe, week of January 5 2015

20 Comments
6 years ago

Premium Last week of the year gets underway.

18 Comments
6 years ago

Premium Update 12/22: January Effect Candidates 2014/2015

5 Comments
6 years ago
6 years ago

Premium Update 12/8 January Effect Candidates 2014/2015

2 Comments
6 years ago